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Abstract
Introduction Bisphosphonates are currently the medical
treatment most often used in children with osteogenesis
imperfecta (OI). The purpose of this retrospective pre–post
study was to evaluate the efﬁcacy of treatment with bis-
phosphonates. We measured the effect by evaluating the
number of outpatient department consultations and opera-
tive interventions before and after treatment with bis-
phosphonates in children with OI.
Methods and materials Outpatient department consulta-
tion and operative intervention frequencies before and after
treatment with bisphosphonates were registered. Children
who had at least 2 years of medical records before treat-
ment and at least 2 years after treatment were used in this
study.
Results Of 118 children who were treated with bisphos-
phonates, 51 (23 boys and 28 girls) fulﬁlled the inclusion
criteria. Statistical analysis revealed a signiﬁcant decrease
in outpatient department consultations (P\0.000) and
operative intervention (P\0.003) before and after bis-
phosphonate treatment.
Conclusion The pre-post design of our study shows a
signiﬁcant reduction of the number of outpatient depart-
ment consultations and operative interventions in patients
with OI after treatment with bisphosphonates.
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Introduction
Osteogenesisimperfecta(OI)isaninheritedconnectivetissue
disorder that has been classiﬁed into four major subtypes by
Sillence [1] based on genetic, radiographic and clinical con-
siderations. Mutations in the COL1A1 and COL1A2 genes,
that codify for type I collagen, are responsible for more than
90%ofallcasesofOI.TypeIcollagenprovidesstructureand
strengthinbone,skinandotherconnectivetissues[2].Oneof
the outcomes of the changes in bones of patients with osteo-
genesis imperfecta is the presence of osteopenia, that in itself
is a factor in the increased fracture risk.
The aims of treatment for patients with OI are to reduce
pathologicfracturerates,minimizechronicpain,preventlong
bone deformities and scoliosis, and maximize mobility. Sur-
gical placement of intramedullary rods may be an essential
contributiontopreventorcorrectlongbonedeformities[3–5].
Bisphosphonates, a group of stable analogs of pyro-
phosphates, are potent inhibitors of bone resorption and
bone turnover and are used in the treatment of osteopenia
[6]. Bisphosphonates are currently the medical treatment
most often used in children with moderate to severe OI. In
previous studies, increased bone mineral density (BMD)
and a decreased incidence of fractures due to bisphospho-
nate therapy were observed in children with OI [7–10].
Treated children reported improved mobility, ambulation
and relief from chronic pain [11–13].
The purpose of this retrospective pre–post study is to eval-
uate the clinical efﬁcacy of treatment with bisphosphonates.
Materials and methods
Outcomes in children with OI before and after treatment
with bisphosphonates were studied in a pre–post study
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formed on all the children by the Department of Paediatric
Orthopaedic Surgery, Wilhelmina Children’s Hospital
(WKZ) of the University Medical Center in Utrecht,
The Netherlands, between February 1988 and December
2009.
Because patient data were charted over different time
periods per patient, annual mean pre- and post-intervention
rates were created and compared. Furthermore, bis-
phosphonate treatment was started for many patients
shortly after referral to our center. Hence, it was impossible
to compare all parameters before and after treatment. In
order to compare these mean pre- and post intervention
rates correctly, the inclusion of children was allowed on
statistical grounds if they were treated a minimum of
2 years before and after starting the bisphosphonates.
Outcome parameters were the number of outpatient
department consultations and operative interventions
before and after treatment with bisphosphonates.
Statistical analysis
Differences between results before and after bisphospho-
nate treatment were tested for signiﬁcance using the Wil-
coxon signed-rank test as we could not assume that the
population was normally distributed. To justify our state-
ments about a possible spontaneous age-related decline in
outpatient department consultations and operative inter-
ventions in children with OI before treatment with
bisphosphonates, a trend analysis was performed. Fur-
thermore, aggregated data was used in a multiple linear
regression including interaction terms in order to estimate
the effect of bisphosphonate treatment. Finally, the poten-
tial inﬂuences of disease severity and initiation of treatment
were evaluated using multiple linear regression analysis.
P\0.05 was considered statistically signiﬁcant. Statistical
analyses were performed using the Statistical Package of
Social Sciences (SPSS), version 16.0.
Results
Between February 1988 and December 2009, 201 patients
were diagnosed with OI, among whom 118 were treated
with bisphosphonates, starting in 1998. Of these 118 chil-
dren, 51 (23 boys and 28 girls) fulﬁlled the inclusion cri-
teria and were used in this study (Fig. 1). In these patients,
a lumbar spine BMD and a protocol check-up were
obtained at the beginning of bisphosphonate treatment and
at intervals of approximately 1 year afterwards. Immobi-
lization of children with OI often results in vitamin D and
calcium deﬁciency. Accordingly, in the protocol, all
patients received a daily supplement of 1,200 IU vitamin D
and 500 mg calcium during bisphosphonate treatment.
Twenty-four children were diagnosed as having OI type
I, thirteen had type III, twelve had type IV, and the OI type
of two patients was unknown. Twenty-six patients were
treated with risedronate, ﬁfteen with pamidronate, two with
alendronate, and eight with pamidronate (who switched
later to risedronate) (Table 1).
Statistical analysis revealed changes in the numbers of
outpatient department consultations and operative inter-
ventions after treatment.
Wilcoxon signed-rank test
Outpatient department consultations
The number of outpatient department consultations
decreased from 3.35 (SD 2.07) per year during the period
before bisphosphonate treatment to 2.14 (SD 2.12) per year
in the period after treatment (P\0.000) (Table 2).
Operative interventions
The number of operative interventions decreased from 0.73
(SD 0.47) per year during the period before bisphosphonate
treatment to 0.38 (SD 0.45) per year in the period after
treatment (P\0.003) (Table 3).
Fig. 1 Trial proﬁle
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In the trend analysis, we observed an increase (RC = 0.27)
in outpatient department consultations every year in the
group before bisphosphonate treatment.
Unfortunately, trend analysis was impossible to apply to
the number of operative interventions before treatment with
bisphosphonates due to a poor distribution of measurements.
Multiple linear regression analysis
In the multiple linear regression analysis, age and bis-
phosphonates represented 70% of the effect on the number
of outpatient department consultations. This interaction
effect was signiﬁcant (P[0.000). The amount of outpa-
tient department visits declined with increasing age. No
signiﬁcant differences in outpatient department visits
between the patients with and without bisphosphonate
treatment were found when analyzed for the whole age
range.Beforetheageofseven,patientswithbisphosphonate
use, had relatively more outpatient department visits as
compared to patients that where not on bisphosphonate
medication. With increasing age however, the amount of
outpatient department visits with bisphosphonate use was
increasingly less as compared to the patients that did not use
bisphosphonates at that same age. There was no relevant or
signiﬁcant inﬂuence of disease severity on the number of
outpatient department consultations or operations.
Discussion
In the pre-post study design, bisphosphonate therapy was
found to decrease the frequency of outpatient visits and
surgical intervention.
Table 1 General characteristics of our study population
Age
a 10 (SD 4,7)
Male/female 23/28
Total 51
Type OI
I2 4
III 13
IV 12
Unknown 2
Bisphosphonates
Risedronate
b 34
Pamidronate
c 15
Alendronate
d 2
a Mean in years
b Administered 1dd 5 mg orally
c Administered intravenously at a dose of 2 mg/kg given every
3 months
d Administered 70 mg orally once a week
Table 2 Outpatient department consultation: statistical analysis by
Wilcoxon signed-rank test
N Mean SD Minimum Maximum
Without bisph 51 3.35 2.12 0.44 9.50
With bisph 51 2.14 2.08 0 9.33
Without bisph—with bisph
Test statistics
b
Z -4.312
a
Asymp. sig. (two-tailed) .000
a Based on negative ranks
b Wilcoxon signed-rank test
Table 3 Operative intervention: statistical analysis by Wilcoxon
signed-rank test
N Mean SD Minimum Maximum
Without bisph 32 0.73 0.47 0.1 1.67
With bisph 32 0.38 0.45 0 1.75
With bisph—without bisph
Test statistics
b
Z -3.018
a
Asymp. sig. (two-tailed) .003
a Based on positive ranks
b Wilcoxon signed-rank test
Fig. 2 Number of outpatient department visits in children with OI
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bisphosphonate therapy in OI used a retrospective study
design. Limiting factors of these studies are considered to
be the selection bias and the dependency on the availability
and accuracy of the medical records. It is often hard to
obtain a homogeneous control group since OI is associated
with wide variations between individuals and variations
over time within one person. Because our study is based on
an examination of existing data, a pre–post retrospective
chart review was chosen.
Other factors besides the bisphosphonate therapy might
contribute to the decrease in treatment frequency in OI
patients. These factors include the age-related acquisition
of motor skills and an increase in BMD due to entrance into
puberty [14, 15].
In our population, however, the number of outpatient
visits increased before bisphosphonate treatment. There-
fore, the correction due to age-related decline was con-
sidered insigniﬁcant.
Theeffectofthebisphosphonatetreatmentonthedecrease
of the number of outpatient department visits seemed to
increasewithincreasingage(Fig.2).Atayoungagechildren
with bisphosphonates had more outpatient department visits
as compared to children that were still without bisphospho-
nate use at that same age, probably because of extra hospital
visits associated with intravenous bisphosphonate treatment
(4–5 infusions per year). At an older age, most children
used oral bisphosphonates, and less outpatient department
visitswere seen as comparedto patientsatthatsameage that
were still without bisphosphonate use.
Other factors that inﬂuence the response to bisphos-
phonates in OI remain unclear. Previous studies have
shown differences in effects on DEXA parameters between
patients with OI types III and IV [15].
Also, a relationship between start of treatment at an
early age and a better outcome has been reported, sug-
gesting the need for early diagnosis and initiation of
treatment [8]. In the pre-post analysis in our study, we
could not ﬁnd a signiﬁcant relationship between differ-
ences in response to bisphosphonates and disease severity
or age at initiation of treatment. As for the inﬂuence of the
use of ﬁxed or extendable rods we assumed no difference
since, for the surgical placement of intramedullary rods,
regular replacement is needed with ﬁxed rods, and more
complications are seen with the use of extendable rods.
The observed increasing decrease in outpatient depart-
ment visits with increasing age is believed to reﬂect a
decrease in bone-related disease such as low BMD,
increased fracture risk, chronic pain and decreased mobility
[7–13]. We believe that the decrease in outpatient depart-
ment visits is comparable to the fracture rate declines
presented by others when using bisphosphonates as a
medical treatment for OI.
However, we have not encountered literature in which
the clinical parameters were compared before and after
bisphosphonate treatment. Thus, a critical comparison with
results presented by others is not possible due to a lack of
reference material.
In conclusion, the results of our study show that bis-
phosphonates can signiﬁcantly reduce the number of out-
patient department consultations and operative interventions
in patients with OI.
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